Could your own immune cells fight ovarian cancer? tiny trial aims to find out

NCT ID NCT07651124

Recruiting now Disease control Sponsor: Yong Wha Moon Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether a patient's own tumor-fighting immune cells (called TILs) can be safely used to treat recurrent ovarian cancer. Researchers take a sample of the tumor, grow the immune cells in a lab, and then inject them back into the patient. Only 6 people will take part, and the main goal is to check for side effects, not yet to see if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous tumor-infiltrating lymphocytes (TILs)
What this could lead to: If it works, this could point toward a new treatment option for recurrent ovarian cancer using a patient's own immune cells.
What could go wrong: This is a very early safety trial with only 6 participants, so it is too small to prove effectiveness. The treatment involves chemotherapy and high-dose IL-2, which can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT OVARIAN CANCER

Contacts and locations

Locations

Bundang CHA Medical Center
RECRUITING

Gyeonggi-do, Bundang-gu, 13520, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.